CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+9.19%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(-9.9%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
93
Reduced
281
Closed
40
Top Buys
| 1 |
NVIDIA
NVDA
|
$40.6M |
| 2 |
Apple
AAPL
|
$9.08M |
| 3 |
Applied Materials
AMAT
|
$5.39M |
| 4 |
Arista Networks
ANET
|
$5.26M |
| 5 |
Amphenol
APH
|
$5.14M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.02M |
| 2 |
Adobe
ADBE
|
$7.95M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$7.6M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$6.84M |
| 5 |
Lam Research
LRCX
|
$5.23M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Relay Therapeutics
RLAY
$631M
| $102K | 0.01% |
15,594
-9,616
| -38% | -$62.7K |
|
302
PVH
PVH
$4.13B
| $99.8K | 0.01% |
943
-5,120
| -84% | -$542K |
|
303
ARS Pharmaceuticals
SPRY
$1.1B
| $96.9K | 0.01% |
11,383
-7,070
| -38% | -$60.2K |
|
304
Aurinia Pharmaceuticals
AUPH
$1.54B
| $95.9K | 0.01% |
16,802
-11,000
| -40% | -$62.8K |
|
305
Cogent Biosciences
COGT
$1.68B
| $94.7K | 0.01% |
11,232
-8,718
| -44% | -$73.5K |
|
306
89bio
ETNB
$1.36B
| $92.6K | 0.01% |
11,560
-6,340
| -35% | -$50.8K |
|
307
Grifois
GRFS
$6.59B
| $90.4K | 0.01% |
14,334
-9,127
| -39% | -$57.5K |
|
308
CureVac
CVAC
$1.21B
| $89.6K | 0.01% |
26,351
-16,668
| -39% | -$56.7K |
|
309
Kiniksa Pharmaceuticals
KNSA
$2.54B
| $88.4K | 0.01% |
4,734
-2,974
| -39% | -$55.5K |
|
310
Harrow
HROW
$1.4B
| $86.8K | 0.01% |
4,157
-2,588
| -38% | -$54.1K |
|
|
BCYC
311
Bicycle Therapeutics
BCYC
$499M
| $85.4K | 0.01% |
4,220
-2,639
| -38% | -$53.4K |
|
|
HSAI
312
Hesai Group
HSAI
$3.31B
| $83.8K | 0.01% |
20,000
| – | – |
|
|
AUTL
313
Autolus Therapeutics
AUTL
$375M
| $81.6K | 0.01% |
23,434
-3,600
| -13% | -$12.5K |
|
314
AnaptysBio
ANAB
$577M
| $80.4K | 0.01% |
3,208
-1,915
| -37% | -$48K |
|
315
Evolus
EOLS
$485M
| $79.8K | 0.01% |
7,355
-3,614
| -33% | -$39.2K |
|
316
Scholar Rock
SRRK
$3.18B
| $78.1K | 0.01% |
9,370
-4,498
| -32% | -$37.5K |
|
317
Arcturus Therapeutics
ARCT
$453M
| $77K | 0.01% |
3,163
-1,990
| -39% | -$48.5K |
|
|
SAGE
318
DELISTED
Sage Therapeutics
SAGE
| $76.8K | 0.01% |
7,070
-4,484
| -39% | -$48.7K |
|
|
PETQ
319
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $76.5K | 0.01% |
3,470
-2,173
| -39% | -$47.9K |
|
320
Pliant Therapeutics
PLRX
$103M
| $76.2K | 0.01% |
7,087
-4,494
| -39% | -$48.3K |
|
321
Travere Therapeutics
TVTX
$1.62B
| $73.5K | 0.01% |
8,945
-5,707
| -39% | -$46.9K |
|
322
Prime Medicine
PRME
$556M
| $72.5K | 0.01% |
14,101
-8,277
| -37% | -$42.5K |
|
323
Erasca
ERAS
$454M
| $72K | 0.01% |
30,527
+1,514
| +5% | +$3.57K |
|
324
Wave Life Sciences
WVE
$1.53B
| $71.8K | 0.01% |
14,388
-9,085
| -39% | -$45.3K |
|
325
Lexicon Pharmaceuticals
LXRX
$407M
| $71.3K | 0.01% |
42,469
-4,461
| -10% | -$7.49K |
|